Last updated: 2026-09-08 22:07:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Regeneron Pharmaceuticals Inc. (REGN) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $810.66, with a market capitalization of $85.22B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $541.00 to $859.34. This page covers its latest market performance, valuation, price trends and company information.
$85.22B | |
$814.36 | |
$1,211.20 | |
$4.61 | |
$827.72 | |
360.95K | |
846.60K | |
-- | |
$859.34 | |
$541.00 | |
-- | |
-- |
Regeneron Pharmaceuticals Inc. (REGN) is trading at $812.15 in after-hours trading as of 2026-09-08 22:01:00, down 1.88% ($15.58) from the regular-session close of $827.72.
After-hours trading shows how investors are pricing REGN after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Regeneron Pharmaceuticals Inc. (REGN) moved from $807.71 to $810.66, representing a gain of 0.36% ($2.95).
The stock traded between $779.08 and $859.34 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 662.75 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 84.7%
REGN is currently trading at $810.66, placing it 84.7% of the way from its 52-week low of $541.00 to its 52-week high of $859.34. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 15410 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Regeneron Pharmaceuticals Inc. (REGN) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.